Healthcare and Pharmaceutical Sector
The healthcare and pharmaceutical sectors saw major advancements in oncology and diagnostics, led by Moderna and Merck's successful phase 3 mRNA vaccine trial and an FDA approval for Jazz Pharmaceuticals' gastric cancer treatment. Major corporate expansions and M&A activity also picked up, including Sword Health acquiring Headspace and Roche teaming with Eli Lilly on an Alzheimer's blood test. Meanwhile, Medicare rolled out a GLP-1 pilot program that excludes millions of enrollees with preexisting conditions.
Sword Health has agreed to acquire mental health company Headspace through a cash purchase of its parent company, OrangeDot. The transaction combines two digital health unicorns and is scheduled to become effective on September 14, following a material change filing submitted to the Massachusetts Health Policy Commission on July 22. Sword Health recently raised $40 million in 2025 at a valuation exceeding $4 billion, bringing its total funding to $493 million. The acquisition broadens Sword Health's platform beyond its core virtual physical therapy offering into mental health services. Financial terms of the transaction were not disclosed in the regulatory paperwork.
The Food and Drug Administration approved Jazz Pharmaceuticals' Ziihera as an initial treatment for HER2-positive gastroesophageal adenocarcinomas. The expanded clearance moves the bispecific antibody from a niche indication in biliary tract cancer—which generated $24.8 million in 2025 revenue—into a frontline setting with a market opportunity exceeding $1.5 billion. In clinical testing, regimens combining Ziihera and chemotherapy reduced disease progression or death by 35% compared to Roche's Herceptin and chemotherapy. Zymeworks, which originally discovered the drug, received a $250 million payment following the approval and remains eligible for up to $1.3 billion in additional milestones.
Moderna and Merck's personalized mRNA cancer vaccine reduced the risk of melanoma recurrence and spread in a phase 3 trial of 1,137 high-risk patients, marking the first time an mRNA-based neoantigen vaccine has cleared a late-stage efficacy hurdle. The vaccine, called intismeran, is tailored to each patient's tumor mutations and administered after surgery alongside Merck's Keytruda immunotherapy; patients receiving both showed statistically significant improvement in recurrence-free survival and distant metastasis-free survival versus Keytruda alone. Moderna's stock surged approximately 177% to around $174 on August 19, with a significant gain in market value, while Merck climbed nearly 13% and the broader Nasdaq Biotechnology Index rose sharply to a record. The companies plan to seek regulatory approval immediately, with potential market entry as early as 2027, though they have not yet released detailed efficacy numbers or overall survival data, which will be shared at an upcoming medical conference. Key commercial hurdles remain: manufacturing a bespoke vaccine for each patient takes several months, creating delays for rapidly progressing cancers, and the approach must prove effective in other cancer types beyond melanoma. Barclays estimates the therapy could generate substantial melanoma sales by 2035 on a majority market share, while JPMorgan and Citi cautioned that the high personalization threshold and unproven efficacy in other cancers pose commercialization risks.